Mucosal Immune Responses Against Neisseria Gonorrhoeae Following Meningococcal Immunization in Healthy Young Adults

  • STATUS
    Recruiting
  • days left to enroll
    36
  • participants needed
    60
  • sponsor
    National Institute of Allergy and Infectious Diseases (NIAID)
Updated on 23 October 2022
Accepts healthy volunteers

Summary

This is a Phase 2 mechanistic clinical trial to assess the systemic and mucosal immunogenicity of the multicomponent meningococcal serogroup B vaccine (4CMenB or Bexsero (R)) (group 1, 40 subjects) against Neisseria gonorrhoeae, using a placebo vaccine (normal saline) as a comparator (group 2, 10 subjects). There will be approximately 50 participants, ages 18-49, both male and non-pregnant female subjects, enrolled at 1 site in the US. The goal will be to ensure adequate representation of subjects by sex in both treatment groups. The enrollment will be stratified by both sex and treatment arm. During enrollment of the "biopsy cohort" male and non-pregnant female subjects will be randomized 4:1 to either 4CMenB or placebo, up to a maximum of 10 male and 10 non-pregnant female subjects. Group 1 (approximate N=40) will receive two doses of 4CMenB on Day 1 and Day 29. Group 2 (approximate N=10) will receive two placebo injections on Day 1 and Day 29. Both groups will receive a single-dose prefilled syringe that is administered intramuscularly (0.5-mililiter each). The duration of each subject's participation is approximately 8 months, from recruitment through the last study visit, and the length of the study is estimated for 14 months. The primary objective is to characterize the rectal mucosal Immunoglobulin G IgG antibody response to Neisseria gonorrhoeae (GC) elicited by the 4CMenB vaccine as compared with the placebo vaccine (normal saline) in healthy adult subjects.

Description

This is a Phase 2 mechanistic clinical trial to assess the systemic and mucosal immunogenicity of the multicomponent meningococcal serogroup B vaccine (4CMenB or Bexsero (R)) (group 1, 40 subjects) against Neisseria gonorrhoeae, using a placebo vaccine (normal saline) as a comparator (group 2, 10 subjects). There will be approximately 50 participants, ages 18-49, both male and non-pregnant female subjects, enrolled at 1 site in the US. The goal will be to ensure adequate representation of subjects by sex in both treatment groups. The enrollment will be stratified by both sex and treatment arm. A subset of subjects in each treatment group (N=16 in Group 1, N=4 in Group 2) will undergo rectal mucosal biopsy at two time points (baseline and following the second vaccination) for assessment of tissue Neisseria gonorrhoeae (GC) specific cellular responses. During enrollment of the "biopsy cohort" male and non-pregnant female subjects will be randomized 4:1 to either 4CMenB or placebo, up to a maximum of 10 male and 10 non-pregnant female subjects. All subjects will undergo sampling of mucosal secretions for testing for antibodies against Neisseria gonorrhoeae (GC). Male subjects will undergo oropharyngeal and rectal mucosal sampling, and female subjects will undergo oropharyngeal, vaginal and rectal mucosal sampling. Group 1 (approximate N=40) will receive two doses of 4CMenB on Day 1 and Day 29. Group 2 (approximate N=10) will receive two placebo injections on Day 1 and Day 29. Both groups will receive a single-dose prefilled syringe that is administered intramuscularly (0.5-mililter each). The duration of each subject's participation is approximately 8 months, from recruitment through the last study visit, and the length of the study is estimated for 14 months. The primary objective is to characterize the rectal mucosal Immunoglobulin G (IgG) antibody response to Neisseria gonorrhoeae (GC) elicited by the 4CMenB vaccine as compared with the placebo vaccine (normal saline) in healthy adult subjects. The secondary objectives are: 1) To characterize the serum IgG antibody response to Neisseria gonorrhoeae (GC) elicited by the 4CMenB vaccine as compared with the placebo vaccine in healthy adult subjects, 2) To assess the safety and reactogenicity of 4CMenB in healthy adult subjects.

Details
Condition Gonorrhoea
Treatment Placebo, Meningococcal group B vaccine
Clinical Study IdentifierNCT04722003
SponsorNational Institute of Allergy and Infectious Diseases (NIAID)
Last Modified on23 October 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Must be aged 18-49 years old (inclusive) at the time of vaccination
Must be able to provide written informed consent
Must have a body mass index (BMI) >/= 18.5 and < 35.0 kg/m2
Must be in good health based on physical examination, vital signs _, medical history, safety labs_ (as applicable to the rectal biopsy and no biopsy cohorts) and the investigator's clinical judgment
Vital signs must be within the normal ranges. If a subject has elevated systolic or diastolic blood pressure, subject may rest for 10 minutes in a quiet room and the blood pressure may be retaken
Safety labs must be within the normal ranges and the normal ranges will be
those used by the reference clinical lab
For female subjects only: If a female participant is of childbearing potential _, she must use contraception_ from 30 days before study product administration through the end of study participation
A woman is considered of childbearing potential unless post-menopausal (defined as history of >/= 1 year of spontaneous amenorrhea), or permanently surgically sterilized (bilateral oophorectomy, salpingectomy, hysterectomy)
Acceptable methods of contraception include: abstinence or no sex with a
male, monogamous relationship with a man who had a vasectomy at least 6 months
before the 1st study vaccine, prescription oral contraceptives, intrauterine
device (IUD), birth control implants or injections, contraceptive patch
vaginal ring, condoms and diaphragms/cervical cap with spermicide ("double
Must be available and willing to participate for the duration of this trial
barrier" method)
Willing to provide mucosal samples: vaginal secretions for women and oropharyngeal and rectal secretions for men and women
For the rectal biopsy cohort only, willing to provide rectal biopsies

Exclusion Criteria

Has ever been diagnosed with meningococcal infection or gonococcal infection at any anatomic site
Any history of Chlamydia trachomatis or syphilis infection at any body site in the preceding 12 months
Has ever received any serogroup B meningococcal vaccine
Has known allergy or history of anaphylaxis or other serious adverse reaction to a vaccine or vaccine products
Any positive test result for STI (including Neisseria gonorrhoeae (GC) Chlamydia trachomatis (CT), Rapid Plasma Reagin (RPR) and Human Immunodeficiency Virus (HIV)) at screening
Has severe allergy or anaphylaxis to latex
Female subjects will also be tested for Trichomonas at screening
Has an acute illness or temperature >/= 38.0 degrees Celsius on Day 1
Has a history of a bleeding disorder, or is taking chronic anti-coagulant (e.g. warfarin, direct thrombin inhibitors, heparin products, etc.), anti-platelet, or non-steroidal anti-inflammatory drugs (NSAID) therapy
Has history of autoimmune disease, or clinically significant cardiac, pulmonary, gastrointestinal, hepatic, rheumatologic, or renal disease by history or physical examination
Has history of active malignancy other than squamous cell or basal cell skin cancer, unless there has been surgical excision that is considered to have achieved cure
Subjects with fever or acute illness on the day of vaccination may be re-assessed and enrolled if healthy or only minor residual symptoms remain within 3 days
Has known or suspected congenital or acquired immunodeficiency, or recent history or current use of immunosuppressive therapy
Is post-organ and/or stem cell transplant, whether or not on chronic immunosuppressive therapy
Had major surgery (per the investigator's judgment) within 4 weeks before study entry or planned major surgery during this trial
Has history of diabetes _mellitus type 1 or type 2, including cases controlled with diet alone_
Received live attenuated vaccines from 30 days before first vaccination until 30 days after second vaccination
Received killed or inactivated vaccines from 14 days before first vaccination until 14 days after second vaccination
Received mRNA, viral vector, or any other technology platform Corona Virus Disease-19 (COVID-19) vaccine within 14 days prior to first dose of the study product
Subjects with a history of skin cancer must not be vaccinated at the previous tumor site
Received experimental therapeutic agents within 12 months before first vaccination or plans to receive any experimental therapeutic agents during this trial except for Emergency Use Authorization (EUA) COVID-19 therapy
Anti-cancer chemotherapy or radiation therapy within the preceding 3 years, or long-term (>/= 2 weeks within the previous 3 months) systemic corticosteroid therapy (at a dosage of >/= 0.5 mg/kg/day). Intranasal or topical prednisone (or equivalent) are allowed
Is currently participating or plans to participate in another clinical study which would involve receipt of an investigational product or undergoing a procedure
Received blood products or immunoglobulin in the 3 months before study entry or planned use during this trial
Has major psychiatric illness in the past 12 months that in the opinion of the investigator would preclude participation
Has current alcohol use or current or past abuse of recreational or narcotic drugs by history as judged by the investigator to potentially interfere with study adherence
In the opinion of the investigator cannot communicate reliably, is unlikely to adhere to the requirements of this trial, or has any condition which would limit the ability to complete this trial
Is pregnant or breast feeding
History of isolated gestational diabetes is not an exclusion criterion
For inactivated influenza vaccine, from 7 days before either vaccination until 7 days after either vaccination
COVID-19 vaccination should take priority over administration of the study product
Only exclusionary if, in the opinion of the investigator, they would interfere with safety or endpoint assessment
Only exclusionary if, in the opinion of the investigator, they would interfere with safety or endpoint assessment
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note